从Toll样受体/核因子-κB信号通路探讨中药免疫调节作用机制  

Viewing from the Toll-like Receptor/Nuclear Factor-κB Signaling Pathway to Explore the Immunomodulatory Mechanism of Chinese Drugs

作　　者：周红光[1] 陈海彬[1] 吴勉华[1] 

机构地区：[1]南京中医药大学,南京210029

出　　处：《中国中西医结合杂志》2010年第8期884-888,共5页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：国家自然科学基金项目(No.30973742/C190201);江苏省高校自然科学研究面上项目(No.09KJB360003);江苏省普通高校研究生科研创新项目(No.CX09S_037Z);江苏省中医药管理局科技项目(No.LB09032)

摘　　要：许多中药从整体水平发挥了显著的免疫调节作用,近年来也从细胞、分子、基因等不同水平对其机理进行了大量的探索。本文在中药既往研究成果的基础上,结合Toll样受体/核因子-κB(TLRs/NF-κB)信号通路,对两者的关系进行了简要介绍,指出中药免疫调节作用与TLRs/NF-κB信号通路密切相关,这不仅对进一步深化中药免疫调节药理认识具有重要理论价值,而且对提高中药治疗疾病的疗效和中药新药开发,都具有重要的现实意义。Many Chinese drugs（CHD） have showed their significant effects of integral immuno-regulation,and lots of researches have conducted in recent years for exploring their mechanism from different levels,like cytological,molecular and genetic levels.In this paper,the relation between immuno-regulation of CHD and Toll-like receptors/nuclear factor-κB（TLRs/NF-κB） signaling pathway was introduced in brief based upon the achievements of previous researches.It was pointed out that the two are closely related,to explore mechanism of CHD in this way is meaningful not only for further deepening the theoretical understanding of CHD＇s pharmacological immunoregulation,but also be practically facilitate for enhancing therapeutic efficacy of CHD and developing new CHD.

关 键 词：中药 Toll样受体/核因子-κB信号通路 免疫调节 

分 类 号：R285[医药卫生—中药学]